Meet IAG’s Board at the SSWC
After two online sessions in 2020 and 2022, the Systemic Sclerosis World Congress is finally back in a physical format!
IAG’s team is thrilled to announce our participation in this stimulating session in Prague, scheduled for March 14 – 16, 2024.
As the field of systemic sclerosis continues to advance, the upcoming congress promises to be an incredible moment, bringing together experts, researchers, and professionals from around the globe to discuss and share the latest scientific discoveries surrounding systemic sclerosis (SSc) through interactive sessions.
Dr. Olga Kubassova, IAG’s Founder and President, and Dr. Francesco Del Galdo, IAG’s Scientific Advisory Board member and Associate Professor, Head of Scleroderma Programme at the Leeds Institute of Rheumatic and Musculoskeletal Medicine, will attend this event and meet with multiple stakeholders of the SSc world to exchange cutting-edge insights, share the latest progress IAG has made in the field, and discuss future collaborations.
Dr. Del Galdo will also host, along with his fellow professionals, a Pre-Congress practical session on Thursday, March 14. We hope you already have your spot secured as the course is now fully booked!
For those unfamiliar, SSc is a rare, autoimmune, connective tissue disorder characterized by excessive fibrosis that can affect multiple organ systems and affecting approximately 75 to 300 people per million in the population. Consequently, medical imaging during the diagnosis steps, long-term patient monitoring, and clinical trials are crucial to track changes and attribute the best possible treatment to patients.
We eagerly invite you to join us for a new and stimulating chapter in the World of Scleroderma!
About Image Analysis Group (IAG)
IAG is a unique partner to life sciences companies developing new treatments and driving the hope of upcoming precision medicine. Leveraging expertise in medical imaging and the power of DYNAMIKA™, our proprietary cloud-based platform, IAG de-risks clinical development and delivers life-saving therapies into the hands of patients much sooner. We provide early drug efficacy assessments, intelligent patient recruitment, and predictive analysis of advanced treatment manifestations, thereby lowering investment risk and accelerating study outcomes.
Acting as a medical imaging clinical research organization, IAG’s experts also recognize the significance of a comprehensive approach to asset development. They actively engage in co-development projects with both private and public sectors, demonstrating a commitment to cultivating collaboration and advancing healthcare solutions.
Learn more: www-test.ia-grp.com
Reach out: imaging.experts@ia-grp.com
Follow the Company: Linkedin